Substituted biphenylsulfonamide endothelin antagonists

US6080774A · kind A · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Natesan Murugesan · Lawrenceville, US
• Joel C. Barrish · Richboro, US
• John Lloyd · Yardley, US

Key dates

• Filing date: Oct 8, 1996
• Grant date: Jun 27, 2000
• Expiry date: Oct 8, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D261/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: ##STR2## R.sup.2 and R.sup.3 are each independently (a) hydrogen; PA1 (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ; PA1 (c) halo; PA1 (d) hydroxyl; PA1 (e) cyano; PA1 (f) nitro; PA1 (g) --C(O)H or --C(O)R.sup.6 ; PA1 (h) --CO.sub.2 H or --CO.sub.2 R.sup.6 ; PA1 (i) --SH, --S(O).sub.n R.sup.6, --S(O).sub.m --OH, --S(O).sub.m --OR.sup.6, --O--S(O).sub.m --R.sup.6, --O--S(O).sub.m OH or --O--S(O).sub.m --OR.sup.6 ; PA1 (j) --Z.sup.4 --NR.sup.7 R.sup.8 ; or PA1 (k) --Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10 ; PA1 and the remaining symbols are as defined in the specification.